Cellectar BioSciences Showcases Pipeline Advancements and Radiotherapeutic Platform in New Corporate Presentation
I'm PortAI, I can summarize articles.
Cellectar BioSciences Inc. has unveiled a corporate presentation detailing advancements in its phospholipid drug conjugates (PDCs) for oncology. Highlights include the start of a Phase 1b study for CLR 125 targeting triple negative breast cancer and the completion of an IND package for CLR 225 for pancreatic cancer. The lead asset, iopofosine I 131, has shown significant response rates in a Phase 2b study for Waldenström macroglobulinemia and has received Breakthrough Therapy and PRIME designations. The presentation also covers additional pipeline programs and the company's manufacturing infrastructure.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments